ESTRO 2024 - Abstract Book

S2003

Clinical - Mixed sites, palliation

ESTRO 2024

As indicated in table 1, previous radiotherapy, gross target volume/planning target volume sizes and treatment management to primary cancer were factors identified as influencing OS. Meanwhile, SABR treatment site and treatment management to primary cancer were factors identified that influenced PFS.

Conclusion:

This study showed modest PFS, OS, and post-treatment toxicity outcomes on SABR to oligometastases from RPC and identified potential factors that could influence clinical outcomes.

Keywords: Oligometastasis, SABR, Rare primary cancers

References: